$RTGN Cashflow Statement | Understand Stock

$RTGN

$4.00 +$0.80 (25.0%) Close

$RTGN Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In USD, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cash Flows From (Used In) Operating Activities
Net loss
Adjustments to reconcile net loss to net cash (used in) operating activities
Non-cash items:
Stock-based compensation expense
Acquired in-process research and development
Depreciation expense
Stock issued for services provided
Amortization of ROU asset
Amortization of right of use asset
Expenses allocated by Sanovas on behalf of Company

Changes in operating assets and liabilities:
Increase in accounts payable and accrued liabilities
(Increase) decrease in deferred offering costs
Increase in accrued interest payable
Payment of lease liability
(Increase) in security deposit
Increase in accrued interest

Total adjustments
Net cash (used in) operating activities
Cash Flows (Used In) Investing activities - Equipment purchase
Cash Flows From Financing Activities
Proceeds from collection of stock subscription receivable
Proceeds from issuance of common stock
Proceeds from exercise of options and warrants
Proceeds from shareholders’ notes payable
Proceeds from exercise of stock options and warrants
Advances from related parties, net
Net cash provided by financing activities
Net increase in cash
Cash at beginning of period
Cash at end of period
Supplemental information:
Operating Lease – at inception
Retirement of due to Sanovas through the issuance of common stock to Sanovas Ophthalmology LLC (Note C)
Exchange of common stock by Sanovas Ophthalomology LLC for pre-funded warrants
Exchange of common stock by Sanovas Ophthalmology LLC for pre-funded warrants
Repayment of shareholders’ note payable through the exercise of warrants
Offset of note payable-affiliates through the exercise of warrants
Settlement of account payable through the issuance of common stock

Comments